FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients treated with pembrolizumab in combination with axitinib, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 20.1% for ALT increased, 13.2% for AST increased, 10.8% for lymphocytes decreased, 8.9% for glucose increased, 7.8% for sodium decreased, 6.4% for phosphate decreased, 6.2% for potassium increased, 4.3% for creatinine increased, 3.6% for potassium decreased, 2.1% for bilirubin increased, 2.1% for haemoglobin decreased, 1.7% for alkaline phosphatase increased, 1.5% for prothrombin INR increased, 1.4% for leukocytes decreased, 1.4% for platelets decreased, 1.2% for activated partial thromboplastin time prolonged, 1.2% for neutrophils decreased, 1.2% for sodium increased, 0.7% for calcium decreased, 0.7% for calcium increased, 0.5% for albumin decreased, and 0.2% for glucose decreased.
Danish: 20,1% med forhøjet ALAT; 13,2% med forhøjet ASAT; 10,8% med nedsat lymfocyttal; 8,9% med forhøjet glucose; 7,8% med nedsat natrium; 6,4% med nedsat fosfat; 6,2% med forhøjet kalium; 4,3% med forhøjet kreatinin; 3,6% med nedsat kalium; 2,1% med forhøjet bilirubin; 2,1% med nedsat hæmoglobin; 1,7% med forhøjet alkalisk fosfatase; 1,5% med forhøjet INR (protrombintid); 1,4% med nedsat leukocyttal; 1,4% med nedsat trombocyttal; 1,2% med forlænget aktiveret partiel tromboplastintid
English: Colitis has been reported in patients receiving pembrolizumab (see section 4.8).
Danish: Colitis er rapporteret hos patienter, der fik pembrolizumab (se pkt.
English: The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, sucrose, polysorbate 80 and water for injections.
Danish: - Øvrige indholdsstoffer: L-histidin, L-histidin-hydrochloridmonohydrat, saccharose, polysorbat 80 og vand til injektionsvæsker.
English: Pembrolizumab 10 mg/kg every 3 weeks n=277
Danish: Pembrolizumab 10 mg/kg hver 3. uge n=277
English: One vial of powder contains 50 mg of pembrolizumab.
Danish: Et hætteglas med pulver indeholder 50 mg pembrolizumab.
English: Table 24: Efficacy results for pembrolizumab as monotherapy in KEYNOTE-048 with PD-L1 expression (CPS ≥ 1)
Danish: Tabel 24: Effektresultater for pembrolizumab som monoterapi i KEYNOTE-048 med PD-L1ekspression (CPS ≥ 1)
English: 1Q 2021
Danish: 1. kvartal 2021
English: Corticosteroids should be administered for Grade ≥ 2 events (initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper); pembrolizumab should be withheld for Grade 2 or Grade 3 colitis, and permanently discontinued for Grade 4 colitis (see section 4.2).
Danish: Kortikosteroider skal administreres ved bivirkninger ≥ grad 2 (initialdosis 1-2 mg/kg/dag prednison eller ækvivalent hermed efterfulgt af langsom udtrapning); pembrolizumab skal pauseres ved grad 2- eller grad 3-colitis og seponeres permanent ved grad 4-colitis (se pkt.
English: Patients were randomised (1:1) to one of the following treatment arms:
Danish: Patienterne blev randomiseret i forholdet 1:1 til en af følgende behandlingsarme:
English: The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, sucrose and polysorbate 80.
Danish: - Øvrige indholdsstoffer: L-histidin, L-histidin-hydrochloridmonohydrat, saccharose og polysorbat 80.
English: Pembrolizumab 200 mg every 3 weeks n=64
Danish: Pembrolizumab 200 mg hver 3. uge n=64
English: Based on patients with a confirmed response by independent review, starting from the date the response was first recorded; n=23 for patients previously treated with ipilimumab; n=18 for patients naïve to treatment with ipilimumab Based on Kaplan-Meier estimation
Danish: * Inkluderer patienter uden målbar sygdom ved baseline ved uafhængig radiologisk gennemgang † IRO = Integrated Radiology and Oncology vurdering i henhold til RECIST 1.1 ‡ Baseret på stabil sygdom eller bedre som bedste respons § Baseret på patienter med bekræftet respons ved uafhængig gennemgang, startende fra den dato, hvor respons blev registreret første gang; n=23 for ipilimumab-erfarne patienter; n=18 for ipilimumab-naive patienter ¶ Baseret på Kaplan-Meier-estimering
English: Treatment arm OS rate at 12 months OS rate at 18 months HR (95% CI) p-value Pembrolizumab + Axitinib 90%
Danish: Behandlingsarm OS-rate i måned 12 OS-rate i måned 18 HR (95% CI) p-værdi Pembrolizumab + Axitinib 90%
English: Patients were randomised (1:1:1) to receive pembrolizumab 10 mg/kg every 2 (n=279) or 3 weeks (n=277) or ipilimumab 3 mg/kg every 3 weeks (n=278).
Danish: (n=279) eller 3. uge (n=277) eller ipilimumab 3 mg/kg hver 3. uge (n=278).
English: The primary efficacy outcome measure was ORR as assessed by BICR using RECIST 1.1.
Danish: Det primære resultatmål var ORR baseret på BICR i henhold til RECIST version 1.1.
English: For use in combination, see the SmPC for the concomitant therapies.
Danish: Se produktresuméet for de samtidigt administrerede lægemidler ved anvendelse i kombinationsbehandling.
English: Very common (may affect more than 1 in 10 people) - thyroid gland problems - feeling less hungry - headache; change in your sense of taste - high blood pressure - shortness of breath; cough; hoarseness - diarrhoea; stomach pain; nausea; vomiting; constipation - blisters or rash on palms of hands or soles of feet; skin rash; itching - feeling tired; unusual tiredness or weakness; fever - increased liver enzyme levels in the blood; abnormal kidney function test - pain in the muscles and bones; joint or muscle pain, aches or tenderness; pain in arms or legs
Danish: Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) - problemer med skjoldbruskkirtlen - nedsat appetit - hovedpine; ændret smagssans - højt blodtryk - kortåndethed; hoste; hæshed - diarré; mavesmerter; kvalme; opkastning; forstoppelse - blærer eller udslæt på håndflader eller fodsåler; hududslæt; kløe - træthedsfølelse; usædvanlig træthed eller svaghed; feber - forhøjede leverenzymværdier i blodet; unormale prøveresultater for nyrefunktion - smerter i muskler og knogler; ledsmerter eller muskelsmerter, smerter eller ømhed; smerter i arme eller ben.
English: * Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model Based on stratified Log rank test
Danish: * Hazard ratio (pembrolizumab sammenlignet med kemoterapi) baseret på den stratificerede Cox proportional hazard-model Baseret på stratificeret log rank-test
English: Pembrolizumab 2 mg/kg every 3 weeks
Danish: Pembrolizumab 2 mg/kg hver 3. uge
English: Treatment arm OS rate at 12 months HR (95% CI) p-value Pembrolizumab
Danish: Behandlingsarm 12 måneders OS-rate HR (95% CI) p-værdi Pembrolizumab
English: Figure 5: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-024 (intent to treat population)
Danish: Figur 5: Kaplan-Meier-kurve for progressionsfri overlevelse i hver behandlingsarm i KEYNOTE-024 (intent to treat-population)
English: • a kind of head and neck cancer called head and neck squamous cell carcinoma
Danish: • en bestemt type hoved-halskræft kaldet planocellulært hoved-hals karcinom
English: Figure 1: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-006 (intent to treat population)
Danish: Figur 1: Kaplan-Meier-kurve for samlet overlevelse i hver behandlingsarm i KEYNOTE-006 (intent to treat-population)
English: Number (%) of patients with event Hazard ratio* (95% CI) p-Value
Danish: Antal (%) patienter med hændelse HR* (95% CI) p-værdi
English: Hazard ratio* (95% CI) p-Value
Danish: HR* (95% CI) p-værdi
English: Pembrolizumab 200 mg every 3 weeks n=270
Danish: Pembrolizumab 200 mg hver 3. uge n=270
English: Pembrolizumab 10 mg/kg every 2 weeks:
Danish: Pembrolizumab 10 mg/kg hver 2. uge:
English: Pembrolizumab 200 mg every 3 weeks n=210
Danish: Pembrolizumab 200 mg hver 3. uge n=210
English: Nephritis has been reported in patients receiving pembrolizumab (see section 4.8).
Danish: Nefritis er rapporteret hos patienter, der fik pembrolizumab (se pkt.
English: Figure 3: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-002 (intent to treat population)
Danish: Figur 3: Kaplan-Meier-kurve for progressionsfri overlevelse i hver behandlingsarm i KEYNOTE-002 (intent to treat-population)
English: itchy skin; hair loss - inflammation of the liver - muscle pain, aches or tenderness; joint or muscle pain with swelling; inflammation of the sheath that surrounds tendons - sudden kidney damage; inflammation of the kidneys - swelling; flu-like illness; chills - increased calcium in the blood; increased liver enzyme levels in the blood
Danish: - muskelsmerter eller muskelømhed; ledsmerter med hævelser; smerter i arme eller ben - inflammation i nyrerne; pludseligt opstået nyreskade - kuldegysninger; influenzalignende sygdom - forhøjet indhold af kalcium i blodet; forhøjede leverenzymværdier i blodet.
English: The study excluded patients with EGFR or ALK genomic tumour aberrations; autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks.
Danish: Patienter med EGFR- eller ALK-mutationer i tumor, autoimmun sygdom, der havde krævet systemisk behandling inden for de seneste 2 år, lidelser, som krævede behandling med immunsuppressiva, og patienter, som havde fået mere end 30 Gy torakal strålebehandling inden for de forudgående 26 uger, blev ekskluderet fra studiet.
English: One vial contains 50 mg of pembrolizumab.
Danish: Et hætteglas indeholder 50 mg pembrolizumab.
English: Figure 2: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-006 (intent to treat population)
Danish: Figur 2: Kaplan-Meier-kurve for progressionsfri overlevelse i hver behandlingsarm i KEYNOTE-006 (intent to treat-population)
English: Withhold until adverse reactions recover to Grades 0-1* For patients with Grade 3 or Grade 4 endocrinopathy that improved to Grade 2 or lower and is controlled with hormone replacement, if indicated, continuation of pembrolizumab may be considered after corticosteroid taper, if needed.
Danish: Det kan overvejes at fortsætte behandlingen med pembrolizumab efter langsom udtrapning af eventuel nødvendig kortikosteroidbehandling hos patienter med endokrinopati grad 3 eller grad 4, som bedres til grad 2 eller lavere med hormonsubstitutionsbehandling, hvis det er indiceret.
English: Figure 12: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-045 (intent to treat population)
Danish: Figur 12: Kaplan-Meier-kurve for samlet overlevelse i hver behandlingsarm i KEYNOTE-045 (intent to treat-population)
English: leukocytes); decrease in the number of platelets (bruising or bleeding more easily) - reaction related to the infusion of the medicine - inflammation of the pituitary gland situated at the base of the brain; inflammation of the thyroid; decreased secretion of hormones produced by the adrenal glands - decreased potassium, sodium or calcium in the blood - trouble sleeping - dizziness; lack of energy; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs - dry eye - abnormal heart rhythm - inflammation of the lungs - inflammation of the intestines; dry mouth - red raised rash, sometimes with blisters; acne-like skin problem; inflammation of the skin; dry,
Danish: nedsat udskillelse af hormoner produceret af binyrerne - nedsat indhold af kalium, natrium eller kalcium i blodet - søvnbesvær - svimmelhed; manglende energi; inflammation i nerverne, som medfører følelsesløshed, svaghed og en snurrende fornemmelse eller brændende smerter i arme og ben - tørre øjne - unormal hjerterytme - inflammation i lungerne - inflammation i tarmene; mundtørhed - rødt hævet hududslæt, nogle gange med blæredannelse; aknelignende hudproblemer; inflammation i huden; tør, kløende hud; hårtab
English: Pembrolizumab 10mg/kg every 2 or 3 weeks (pooled)
Danish: Pembrolizumab 10 mg/kg hver 2. eller 3. uge (puljet)
English: Very common (may affect more than 1 in 10 people) - decrease in the number of red blood cells - decreased number of white blood cells; decrease in the number of platelets (bruising or bleeding more easily) - decreased potassium in the blood; feeling less hungry - dizziness; headache; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; change in your sense of taste - shortness of breath; cough - diarrhoea; nausea; vomiting; constipation; stomach pain - skin rash; itching; hair loss - pain in the muscles and bones; joint pain - unusual tiredness or weakness; swelling; fever - abnormal kidney function test
Danish: Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) - nedsat antal røde blodlegemer - nedsat antal hvide blodlegemer; nedsat antal blodplader (øget tendens til at få blå mærker eller øget blødningstendens) - nedsat indhold af kalium i blodet; nedsat appetit - svimmelhed; hovedpine; inflammation i nerverne, som medfører følelsesløshed, svaghed, en snurrende fornemmelse eller brændende smerter i arme og ben; ændret smagssans - kortåndethed; hoste - diarré; kvalme; opkastning; forstoppelse; mavesmerter - hududslæt; kløe; hårtab - smerter i muskler og knogler; ledsmerter - usædvanlig træthed eller svaghed; hævelser; feber - unormale prøveresultater for nyrefunktion.
English: Very common (may affect more than 1 in 10 people) - decrease in the number of red blood cells - reduced thyroid gland activity - feeling less hungry - headache - shortness of breath; cough - diarrhoea; stomach pain; nausea; vomiting; constipation - itching; skin rash - pain in muscle and bones; joint pain - feeling tired; unusual tiredness or weakness; swelling; fever
Danish: Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) - nedsat antal røde blodlegemer - nedsat funktion af skjoldbruskkirtlen nedsat appetit - hovedpine kortåndethed; hoste - diarré; mavesmerter; kvalme; opkastning; forstoppelse - kløe; hududslæt - smerter i muskler og knogler; ledsmerter - træthedsfølelse; usædvanlig træthed eller svaghed; hævelser; feber.
English: Uncommon adrenal insufficiency hypophysitis d, thyroiditis hypophysitis d,
Danish: hypofysitis d, tyroiditis hypofysitis d, tyroiditis e, binyrebarkinsufficiens
English: Pembrolizumab 10 mg/kg every 3 weeks:
Danish: Pembrolizumab 10 mg/kg hver 3. uge:
English: Figure 6: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-024 (intent to treat population)
Danish: Figur 6: Kaplan-Meier-kurve for samlet overlevelse i hver behandlingsarm i KEYNOTE-024 (intent to treat-population)
English: * Hazard ratio (pembrolizumab compared to ipilimumab) based on the stratified Cox proportional hazard model
Danish: * Hazard ratio (pembrolizumab sammenlignet med ipilimumab) baseret på den stratificerede Cox proportional hazard-model
English: KEYNOTE-002: Controlled trial in melanoma patients previously treated with ipilimumab The safety and efficacy of pembrolizumab were investigated in KEYNOTE-002, a multicentre, controlled study for the treatment of advanced melanoma in patients previously treated with ipilimumab and if BRAF V600 mutation-positive, with a BRAF or MEK inhibitor.
Danish: Pembrolizumabs sikkerhed og virkning blev undersøgt i KEYNOTE-002, et kontrolleret multicenterstudie af behandling af fremskredent melanom hos patienter, der tidligere har været behandlet med ipilimumab og med en BRAF- eller MEK-hæmmer, hvis der forekom en BRAF V600-mutation.
English: Ipilimumab Pembrolizumab 10 mg/kg every 2 or 3 weeks (pooled)
Danish: Ipilimumab Pembrolizumab 10 mg/kg hver 2. eller 3. uge (puljet)
English: Administration of pembrolizumab was permitted beyond RECIST-defined disease progression by BICR or beyond discontinuation of pemetrexed if the patient was clinically stable and deriving clinical benefit as determined by the investigator.
Danish: Administration af pembrolizumab var tilladt efter sygdomsprogression i henhold til RECIST baseret på BICR-vurdering eller efter seponering af pemetrexed, hvis patienten var klinisk stabil, og investigator vurderede, at patienten havde en klinisk fordel.
English: cardiac arrhythmia (including atrial fibrillation)
Danish: † (inklusive atrieflimren)
English: The primary efficacy outcome measure was ORR as assessed by independent review using RECIST 1.1.
Danish: Det primære resultatmål var ORR, baseret på en vurdering ved IRO i henhold til RECIST 1.1.
English: Figure 4: Kaplan-Meier curve for recurrence-free survival by treatment arm in KEYNOTE-054 (intent to treat population)
Danish: Figur 4: Kaplan-Meier-kurve for recidivfri overlevelse i hver behandlingsarm i KEYNOTE-054 (intent to treat-population)
English: Absorption
Danish: PRODUKTRESUMÉ
English: Pembrolizumab 2 mg/kg every 3 weeks:
Danish: Pembrolizumab 2 mg/kg hver 3. uge:
English: Treatment arm OS rate at 6 months OS rate at 12 months HR (95% CI)
Danish: Behandlingsarm OS-rate i måned 6 OS-rate i måned 9 HR (95% CI)
English: IV
Danish: HR
English: Hepatitis has been reported in patients receiving pembrolizumab (see section 4.8).
Danish: Hepatitis er rapporteret hos patienter, der fik pembrolizumab (se pkt.
English: KEYTRUDA in combination with axitinib in RCC For RCC patients treated with KEYTRUDA in combination with axitinib, see the Summary of Product Characteristics (SmPC) regarding dosing of axitinib.
Danish: Se produktresuméet for axitinib for oplysninger vedrørende dosering af axitinib for RCC-patienter, der behandles med KEYTRUDA i kombination med axitinib.
English: Pneumonitis has been reported in patients receiving pembrolizumab (see section 4.8).
Danish: Pneumonitis er rapporteret hos patienter, der fik pembrolizumab (se pkt.
English: Intravenous use
Danish: Intravenøs anvendelse i.v.
English: Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator.
Danish: Administration af pembrolizumab var tilladt efter sygdomsprogression defineret i henhold til RECIST, hvis patienten var klinisk stabil, og investigator vurderede, at patienten havde en klinisk fordel.
English: Uncommon (may affect up to 1 in 100 people) - decreased number of white blood cells (lymphocytes and eosinophils) - type 1 diabetes - a condition in which the muscles become weak and tire easily - inflammation of the heart muscle, which may present as shortness of breath, irregular heartbeat,
Danish: Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) - nedsat antal hvide blodlegemer (lymfocytter og eosinofiler) - type 1-diabetes (sukkersyge) - en tilstand hvor musklerne bliver svage og hurtigere bliver trætte - inflammation i hjertemusklen, som kan inkludere kortåndethed, uregelmæssig hjerterytme, træthed eller brystsmerter - inflammation i øjnene; øjensmerter, øjenirritation, kløe eller røde øjne; ubehagelig lysfølsomhed;
English: Not statistically significant after adjustment for multiplicity Based on patients with a best overall response as confirmed complete or partial response from the final analysis
Danish: Baseret på patienter med en bedste samlet respons, der er bekræftet som komplet eller partielt respons fra den endelige analyse
English: Patients had PD-L1 expression with a  1% TPS based on the
Danish: Patienterne havde PD-L1-ekspression med TPS  1% baseret på PD-L1 IHC 22C3 pharmDx
English: PFS rate at 6 months (95% CI) 49.4 (40.3, 57.9) PFS rate at 12 months (95% CI) 23.9 (16.7, 31.7) PFS rate at 24 months (95% CI) 14.6 (8.9, 21.5) ORR
Danish: 5,6 (1,6+; 25,6+) 4,6 (1,4+; 31,4+) NR (1,5+; 38,9+) 5,0 (1,4+; 38,7+)
English: 75 mg/m or carboplatin AUC 5 mg/mL/min intravenously every 3 weeks for 4 cycles followed by pembrolizumab 200 mg and pemetrexed 500 mg/m intravenously every 3 weeks
Danish: AUC 5 mg/ml/min intravenøst hver 3. uge i 4 serier efterfulgt af placebo og pemetrexed 500 mg/m intravenøst hver 3. uge (n=206).
English: Common (may affect up to 1 in 10 people) - lung infection - decrease in the number of platelets (bruising or bleeding more easily); decrease in the number of white blood cell (lymphocytes) - reactions related to the infusion of the medicine - overactive thyroid gland activity; hot flush - decreased sodium, potassium, or calcium in the blood - trouble sleeping - dizziness; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; lack of energy; change in your sense of taste - dry eye - abnormal heart rhythm - high blood pressure - inflammation of the lungs - inflammation of the intestines; dry mouth - red raised rash sometimes with blisters; patches of skin which have lost colour; dry, itchy skin;
Danish: Almindelig (kan forekomme hos op til 1 ud af 10 personer) - lungeinfektion (lungebetændelse) - nedsat antal blodplader (øget tendens til at få blå mærker eller øget blødningstendens); nedsat antal hvide blodlegemer (lymfocytter) - reaktion i forbindelse med infusion af medicinen - overaktiv skjoldbruskkirtel; hedeture - nedsat indhold af natrium, kalium eller kalcium i blodet - søvnbesvær - svimmelhed; inflammation i nerverne, som medfører følelsesløshed, svaghed og en snurrende fornemmelse eller brændende smerter i arme og ben; manglende energi; ændret smagssans - tørre øjne - unormal hjerterytme - højt blodtryk - inflammation i lungerne - inflammation i tarmene; mundtørhed - rødt hævet hududslæt, nogle gange med blæredannelse; pletvise farveændringer i huden (hvide pletter); tør, kløende hud; hårtab; aknelignende hudproblemer - muskelsmerter eller muskelømhed; smerter i arme eller ben; ledsmerter med hævelser - kuldegysninger; influenzalignende sygdom - forhøjede leverenzymværdier i blodet; forhøjet indhold af kalcium i blodet; unormale prøveresultater for nyrefunktion.
English: meningitis (aseptic)
Danish: myastenisk syndrom h, meningitis (aseptisk) encephalitis
English: Permanently discontinue
Danish: Seponer behandlingen permanent
English: Number (%) of patients with event Hazard ratio* (95% CI) p-Value Median in months (95% CI)
Danish: Antal (%) patienter med hændelse Hazard ratio* (HR) (95% konfidensinterval, CI) p-værdi
English: * Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model
Danish: * Hazard ratio (pembrolizumab sammenlignet med kemoterapi) baseret på den stratificerede Cox proportional hazard-model
English: Treatment arm OS rate at 12 months OS rate at 24 months HR (95% CI) p-value Pembrolizumab
Danish: Behandlingsarm OS-rate i måned 12 OS-rate i måned 24 HR (95% CI) p-værdi Pembrolizumab
English: Treatment arm PFS rate at 6 months PFS rate at 12 months HR (95% CI) p-value Pembrolizumab
Danish: Behandlingsarm PFS-rate i måned 6 PFS-rate i måned 12 HR (95% CI) p-værdi Pembrolizumab
English: Common (may affect up to 1 in 10 people) - lung infection - decreased number of white blood cells (neutrophils) with a fever - reaction related to the infusion of the medicine - thyroid gland problems - decreased sodium or calcium in the blood - trouble sleeping - dry eye - abnormal heart rhythm - high blood pressure - inflammation of the lungs - inflammation of the intestines; dry mouth - red raised rash, sometimes with blisters - muscle pain, aches or tenderness; joint pain with swelling; pain in arms or legs - inflammation of the kidneys; sudden kidney damage - chills; influenza like illness - increased calcium in the blood; increased liver enzyme levels in the blood
Danish: Almindelig (kan forekomme hos op til 1 ud af 10 personer) - lungeinfektion (lungebetændelse) - nedsat antal hvide blodlegemer (neutrofiler) med feber - reaktion i forbindelse med infusion af medicinen - problemer med skjoldbruskkirtlen - nedsat indhold af natrium eller kalcium i blodet - søvnbesvær - tørre øjne - unormal hjerterytme - højt blodtryk - inflammation i lungerne - inflammation i tarmene; mundtørhed - rødt hævet hududslæt, nogle gange med blæredannelse